- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01999010
Mental Health Telemetry for Self-Management in Major Depression (MHTV)
Mood journaling is a cornerstone of self-management in major depressive disorder (MDD). Research over the last decade has shown that electronic mood journals are superior to paper ones. One potential advantage of mental health telemetry (MHT), which use cell phones to collect mood journal data, is that electronic journal data can easily be converted into graphical records, allowing people living with MDD to readily spot trends, correlations, or patterns in ways that would be quite challenging using paper diaries. This information should make it easier to recognize and evaluate changes in mental health status -- the first two steps in the process of self-management. The investigators will develop and deploy a visualization module for patients with which to explore their own MHT data sets on the same cell phones which they record their journals, and test the investigators hypotheses that their enhanced MHT system will (i) improve patients' ability to self-manage MDD and (ii) enhance their quality-of-life.
The study is a non-randomized, un-blinded, A-B-A' (modified single-subject withdrawal design, with user choice of treatment or withdrawal in the A' stage) study, to explore the utility of MHT as a tool for enhancing self-management and QoL for persons living with MDD. The aims of this study are to explore the impact of MHT on subjects' self-management and QoL, and to gauge participants' perceptions of MHT's utility.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
We will recruit (n=113) patients with a Diagnostic and Statistical Manual, 4th Ed. (DSM-IV) diagnosis of MDD, confirmed using the MDD section of the M.I.N.I. International Neuropsychiatric Interview (MINI) version 5.0. All recruits will own or use a web-enabled cell phone.
Exclusion Criteria:
- self-disclosed illiteracy;
- blindness;
- inability to be successfully trained in the use of MHT
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Treatment as usual ("A" Stage)
The treatment as usual (TAU) group will continue to receive their usual treatment from their current treatment team - i.e.
MHT will not be introduced during this phase.
|
|
|
Experimental: MHT ("B" Stage)
Patients will be given software for Mental Health Telemetry (MHT), which allows them to record symptom intensity, hospital / ER visits, life events, etc., and to visualize their MHT data.
Patients will be encouraged to make MHT entries once daily at a pre-determined time while in this arm, and will be prompted via text message by the MHT software to do so.
|
MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder.
Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression.
MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
|
|
Experimental: Choice ("A' " Stage)
Patients exiting the MHT arm will be given the choice to continue with MHT for a further two months or whether to resume TAU (i.e., no further use of MHT) for the remaining two months.
|
MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder.
Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression.
MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in self-management ratings
Time Frame: two months and four months
|
Self-management ratings using the three sub-scale scores (maintenance, management, and confidence) of the Sunnybrook Self-Management Scale - Depression (3S-D) instrument at the end of the Treatment-as-Usual phase (two months) as compared to the end of the active treatment phase (four months)
|
two months and four months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Quality-of-life (QoL) ratings
Time Frame: two months and four months
|
Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ) scores at the end of the treatment-as-usual (two months) and active treatment (four months) phases.
We will control for severity of mood symptoms (using mental health telemetry (MHT) composite depression scores) as a covariate of the magnitude of change in QoL outcomes because we expect that some, but not all, of the variance in QoL outcomes will be accounted for in particular by the severity of depression.
|
two months and four months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Retention Rates (Exploratory)
Time Frame: Four months
|
We will report the proportion and 95% confidence interval (CI) of users who opt to continue using MHT in the A' (user choice) phase
|
Four months
|
|
Utilization Rates (Exploratory)
Time Frame: Six months
|
We will report the mean number and 95% CI of times per patient (in the B and A' phases) that MHT data was (i) reported and (ii) visualized.
|
Six months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: David M Kreindler, MD, Sunnybrook Health Sciences Centre
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 186-2013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Gang WangWest China Hospital; The First Hospital of Hebei Medical University; Tianjin... and other collaboratorsRecruitingMajor Depressive Disorder (MDD) | Depression - Major Depressive DisorderChina
-
Brian MickeyNational Institute of Mental Health (NIMH)RecruitingMajor Depressive Episode | Depression - Major Depressive Disorder | Treatment-Resistant Major Depressive DisorderUnited States
-
Unity Health TorontoUniversity of Toronto; Toronto Metropolitan UniversityRecruitingMajor Depressive Disorder (MDD) | Major Depressive Episode | Treatment-Resistant Major Depressive DisorderCanada
-
Stanford UniversityNational Institute of Mental Health (NIMH)Recruiting
-
TakedaRecruitingMajor Depressive DisorderJapan
-
Neurocrine BiosciencesRecruitingMajor Depressive DisorderSpain, Serbia, United States, Bulgaria, Canada, Estonia, Italy, Poland, Taiwan, Australia, South Korea
-
Luye Pharma Group Ltd.Enrolling by invitationMajor Depressive DisorderChina
-
NeuroQore Inc.Makromed Inc.Enrolling by invitationMajor Depressive DisorderUnited States
-
The Royal Ottawa Mental Health CentreNot yet recruitingDepression | Major Depressive Disorder (MDD) | Depressive Episode | Depression - Major Depressive DisorderCanada
-
Aalborg University HospitalRecruitingDepressive Disorder | Depression | Depressive Episode | Depressive Disorders | Depressive Episodes | Depression - Major Depressive Disorder | Depressive Disorder, Major Depressive DisorderDenmark
Clinical Trials on MHT
-
Sunnybrook Health Sciences CentreCompletedMood Disorders | Bipolar DisorderCanada
-
Dr. David KreindlerSunnybrook Health Sciences CentreCompletedUsing Mental Health Telemetry to Predict Relapse and Re-hospitalization in Mood Disorders (PATH-MOD)Bipolar Disorder | Major Depressive Disorder | DysthymiaCanada
-
Sunnybrook Health Sciences CentreMotorola Canada LimitedCompletedBipolar Disorder | Borderline Personality Disorder | CyclothymiaCanada
-
SurgaColl Technologies LimitedUnknownAssessment of HydroxyColl Bone Graft Substitute in High Tibial Osteotomy Wedge Grafting. (HColl_HTO)Osteoarthritis, KneeUnited Kingdom
-
Jacek KubicaTerminatedAcute Coronary Syndrome | Cardiac ArrestPoland
-
The University of Texas Health Science Center,...Recruiting
-
University of JyvaskylaHospital District of Helsinki and Uusimaa; Wellbeing Services County of Central... and other collaboratorsRecruiting